Herantis Pharma Plc Is A Clinical Stage Biotechnology Company Based In Finlanddedicated To Developing Therapies For Neurodegenerative Disordersparticularly Parkinson S Diseasethe Company Has Been Publicly Listed On The Nasdaq First North Growth Market Finland Since 2014Herantis Aims To Create Disease Modifying Treatments That Can Halt Or Reverse Disease Progression The Lead Producther 096Is A Synthetic Peptidomimetic Molecule Designed For Subcutaneous Administrationit Has Shown Promising Results In Early Clinical Trialsdemonstrating Safety And Effective Blood Brain Barrier Penetrationthe Company Is Currently Conducting A Phase 1B Trial To Evaluate The Safety And Tolerability Of Repeated Dosing In Parkinson S Patientsherantis Focuses On Translational Research To Advance Its Therapies Through Regulatory Milestonesensuring Compliance And Strategic Alignment In Its Operations
